Millennium Management Portfolio holdings
Millennium Management, founded in 1989 by Israel (Izzy) Englander and Ronald Shear and headquartered in New York City, is a global multi-strategy hedge fund managing over $71 billion in assets as of late 2024, employing a decentralized model with over 300 independent trading teams. Operating across equities, fixed income, commodities, currencies, and derivatives, the firm uses a mix of quantitative and fundamental strategies, providing its portfolio managers with capital, infrastructure, and autonomy to pursue diverse investment approaches while enforcing strict risk management. With more than 5,400 employees across offices in London, Hong Kong, Singapore, and beyond, Millennium has evolved from its initial $35 million seed capital—partly from the Belzberg family—into a titan of the hedge fund world, known for its ability to attract top talent and deliver consistent returns. Under Englander’s leadership as chairman and CEO, the firm remains a low-profile yet highly influential force in global finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$643M |
| 2 |
AT&T
T
|
+$311M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$306M |
| 4 |
Microsoft
MSFT
|
+$292M |
| 5 |
Ametek
AME
|
+$215M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$887M |
| 2 |
Apple
AAPL
|
+$694M |
| 3 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$616M |
| 4 |
Amazon
AMZN
|
+$596M |
| 5 |
Linde
LIN
|
+$531M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 7.39% |
| 2 | Financials | 6.67% |
| 3 | Healthcare | 6.18% |
| 4 | Industrials | 4.97% |
| 5 | Consumer Discretionary | 4.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1226
MYR Group
MYRG
$5.01B
| $21.7M | 0.01% |
217,969
-174,090
| -44% | -$17.1M |
|
1227
iShares Biotechnology ETF
IBB
$9.45B
| $21.7M | 0.01% |
134,105
-391,394
| -74% | -$65.9M |
|
1228
Innoviva
INVA
$1.6B
| $21.7M | 0.01% |
1,297,110
+599,655
| +86% | +$8.97M |
|
1229
Elevance Health
ELV
$81.5B
| $21.7M | 0.01% |
58,139
-81,527
| -58% | -$31M |
|
1230
CALL
DraftKings
DKNG
$12.2B
| $21.7M | 0.01% |
+450,000
| New | +$23.9M |
|
1231
Centene
CNC
$30.5B
| $21.6M | 0.01% |
347,153
-465,501
| -57% | -$31.1M |
|
1232
Whirlpool
WHR
$2.49B
| $21.6M | 0.01% |
105,787
+9,557
| +10% | +$2.1M |
|
|
DSPG
1233
DELISTED
DSP Group Inc
DSPG
| $21.6M | 0.01% |
984,107
+923,354
| +1,520% | +$16.5M |
|
|
HSKA
1234
DELISTED
Heska Corp
HSKA
| $21.5M | 0.01% |
83,302
+9,961
| +14% | +$2.54M |
|
1235
HubSpot
HUBS
$12.9B
| $21.5M | 0.01% |
31,849
+879
| +3% | +$566K |
|
1236
Steven Madden
SHOO
$3.17B
| $21.5M | 0.01% |
536,078
+348,914
| +186% | +$14.4M |
|
1237
CALL
Global Payments
GPN
$24.1B
| $21.5M | 0.01% |
136,500
+131,700
| +2,744% | +$22.9M |
|
1238
EastGroup Properties
EGP
$11.2B
| $21.5M | 0.01% |
129,003
+103,548
| +407% | +$18M |
|
|
BOAC
1239
DELISTED
Bluescape Opportunities Acquisition Corp.
BOAC
| $21.5M | 0.01% |
2,191,473
-348,300
| -14% | -$3.41M |
|
1240
PUT
Dollar Tree
DLTR
$24.8B
| $21.5M | 0.01% |
224,200
| – | – |
|
1241
CRISPR Therapeutics
CRSP
$4.69B
| $21.5M | 0.01% |
191,700
+99,061
| +107% | +$12.4M |
|
1242
F5
FFIV
$22B
| $21.4M | 0.01% |
107,908
-150,186
| -58% | -$30M |
|
1243
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$3.54B
| $21.4M | 0.01% |
221,542
-100,105
| -31% | -$8.52M |
|
|
VAQC
1244
DELISTED
Vector Acquisition Corporation II Class A Ordinary Shares
VAQC
| $21.4M | 0.01% |
2,195,765
-30,693
| -1% | -$300K |
|
1245
Endava
DAVA
$165M
| $21.4M | 0.01% |
157,467
+31,855
| +25% | +$4.11M |
|
1246
Fortive
FTV
$18B
| $21.4M | 0.01% |
402,044
-2,284,089
| -85% | -$125M |
|
|
IPOD
1247
DELISTED
Social Capital Hedosophia Holdings Corp. IV
IPOD
| $21.3M | 0.01% |
2,108,888
+1,468,554
| +229% | +$14.8M |
|
1248
Reliance Steel & Aluminium
RS
$20.6B
| $21.3M | 0.01% |
149,664
+119,725
| +400% | +$18M |
|
|
AZUL
1249
DELISTED
Azul
AZUL
| $21.3M | 0.01% |
1,061,769
+969,589
| +1,052% | +$21.3M |
|
1250
Myriad Genetics
MYGN
$476M
| $21.3M | 0.01% |
659,591
-233,929
| -26% | -$7.77M |
|
Similar funds
Millennium Management's Q3 2021 Portfolio in Review
As of Q3 2021, Millennium Management held 7,698 positions worth $167B, up 2.3% from $163B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Millennium Management deployed $8.65B of net new capital in Q3 2021, opening 1,244 new positions and adding to 2,720 existing holdings. Its largest new stake was Sight Sciences: 1,577,092 shares worth $35.8M.
By sector, the portfolio is most concentrated in Technology at 7.4% of assets, down from 7.8% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Apple, an estimated $694M trimmed.
- Millennium Management's largest Q3 2021 buy was Sight Sciences: 1,577,092 shares worth $35.8M.
- Millennium Management added most to State Street SPDR S&P 500 ETF Trust in Q3 2021, an estimated $643M increase.
- Millennium Management's biggest Q3 2021 reduction was Apple, cutting an estimated $694M.
- Millennium Management fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $887M.
- Millennium Management's ten largest holdings make up 18% of its $167B portfolio in Q3 2021.
- Millennium Management opened 1,244 new positions and closed 981 in Q3 2021.
- Millennium Management's portfolio value rose 2.3% quarter-over-quarter to $167B.
Based on Millennium Management's 13F filing for Q3 2021, filed 15 Nov 2021.